ADA 2017

In part 5, the conclusion of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about upcoming research studies on patient adherence.

In part 4 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about his interest in the comparative analysis of various drug classes and their real-world implications.

In part 3 of this Exclusive Interview, Dr. Swapnil N Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about patient claims of hypoglycemia while on DPP4 treatment.

In part 2 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the ultimate savings in the use of DPP4s — reduced risk of hypoglycemia.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have another exclusive interview from the ADA 2017 Scientific Sessions in San Diego, CA. David Zeng, PhD, is CEO of Glutalor Medical Inc. in Philadelphia, PA. …

In this Exclusive Interview transcript, David Zeng discusses the iWel continuous glucose monitor, which is pending FDA approval for U.S. distribution, and the CGM's functioning costs, patient education, and benefit for doctors who will use this with their patients.

In this Exclusive Interview, David Zeng talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about their newest CGM, iWel, which is pending FDA approval for distribution in the U.S. Dr. Zeng discusses the functioning of the product, costs, patient education, as well as benefit for the doctors seeking to use this with their patients.

In part 1 of this Exclusive Interview, David Zeng, CEO of Glutalor Medical Inc.,  talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the iWel, their newest CGM product, which is being submitted for FDA approval.

In part 2 of this Exclusive Interview, David Zeng talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about competing in the ever-growing CGM market.

In part 3 of this Exclusive Interview, David Zeng talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the timing of the launch of the iWel in the U.S. and anticipated cost.